CN101686680B - 作为p2x7调节剂的双环杂芳基化合物及其用途 - Google Patents

作为p2x7调节剂的双环杂芳基化合物及其用途 Download PDF

Info

Publication number
CN101686680B
CN101686680B CN200880014110.6A CN200880014110A CN101686680B CN 101686680 B CN101686680 B CN 101686680B CN 200880014110 A CN200880014110 A CN 200880014110A CN 101686680 B CN101686680 B CN 101686680B
Authority
CN
China
Prior art keywords
mol
substituted
methyl
disease
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880014110.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101686680A (zh
Inventor
M·G·凯利
J·金凯德
Y·方
Y·曹
C·卡波
S·高鲁加利
Z·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ivotec America Inc
Original Assignee
Reynolds
Ivotec America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reynolds, Ivotec America Inc filed Critical Reynolds
Publication of CN101686680A publication Critical patent/CN101686680A/zh
Application granted granted Critical
Publication of CN101686680B publication Critical patent/CN101686680B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
CN200880014110.6A 2007-03-09 2008-03-07 作为p2x7调节剂的双环杂芳基化合物及其用途 Active CN101686680B (zh)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US90604907P 2007-03-09 2007-03-09
US60/906,049 2007-03-09
US91812307P 2007-03-15 2007-03-15
US91826107P 2007-03-15 2007-03-15
US91826007P 2007-03-15 2007-03-15
US91808607P 2007-03-15 2007-03-15
US60/918,261 2007-03-15
US60/918,123 2007-03-15
US60/918,260 2007-03-15
US60/918,086 2007-03-15
US838507P 2007-12-20 2007-12-20
US838607P 2007-12-20 2007-12-20
US837007P 2007-12-20 2007-12-20
US61/008,370 2007-12-20
US61/008,385 2007-12-20
US61/008,386 2007-12-20
US1067208P 2008-01-10 2008-01-10
US61/010,672 2008-01-10
PCT/US2008/003175 WO2008112205A1 (en) 2007-03-09 2008-03-07 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof

Publications (2)

Publication Number Publication Date
CN101686680A CN101686680A (zh) 2010-03-31
CN101686680B true CN101686680B (zh) 2015-12-09

Family

ID=39759833

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880014110.6A Active CN101686680B (zh) 2007-03-09 2008-03-07 作为p2x7调节剂的双环杂芳基化合物及其用途

Country Status (8)

Country Link
US (1) US8093265B2 (https=)
EP (1) EP2124562B1 (https=)
JP (1) JP2010520875A (https=)
CN (1) CN101686680B (https=)
CA (1) CA2680275C (https=)
DK (1) DK2124562T3 (https=)
ES (1) ES2576643T3 (https=)
WO (1) WO2008112205A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI464148B (zh) * 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
BRPI0709596A2 (pt) 2006-03-16 2011-07-19 Renovis Inc compostos bicicloeteroarila como moduladores de p2x7 e seus usos
WO2007109172A2 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
CA2655675A1 (en) * 2006-07-06 2008-01-10 Glaxo Group Limited Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
US8212723B2 (en) * 2008-08-27 2012-07-03 Qualcomm Incorporated Method and apparatus for determining at a predetermined granularity the direction and range of a transmitting mobile device
CN103687860B (zh) * 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
EA024204B1 (ru) 2012-01-20 2016-08-31 Актелион Фармасьютиклз Лтд. Производные гетероциклических амидов в качестве антагонистов p2xрецептора
AR093921A1 (es) 2012-12-12 2015-06-24 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x7
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7
KR102222220B1 (ko) 2013-01-22 2021-03-03 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
WO2015187905A1 (en) * 2014-06-05 2015-12-10 Merck Patent Gmbh Novel quinoline derivatives and their use in neurodegenerative diseases
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN121843919A (zh) * 2023-09-13 2026-04-10 苏文生命科学有限公司 作为p2x7受体拮抗剂的n-芳基苯甲酰胺衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492378B1 (en) * 1998-08-11 2002-12-10 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsivants

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588736A (en) * 1897-08-24 Egg-tester
FR2450E (fr) 1903-02-09 1904-04-07 Sulzer Freres Soc Palier pour pompes et autres machines analogues
DE2343984A1 (de) 1973-08-31 1975-03-13 Hoechst Ag Wasserunloesliche disazomethinfarbstoffe, verfahren zu ihrer herstellung und ihre verwendung
US3950343A (en) * 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3900477A (en) * 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
SU749832A1 (ru) 1978-03-24 1980-07-23 Предприятие П/Я М-5885 Способ получени амино- -оксифенантридонов
GB2044254B (en) 1979-01-26 1983-01-26 Wyeth John & Brother Ltd Piperidine derivatives
EP0093488A3 (en) 1982-03-18 1984-05-23 Beecham Group Plc Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them
DE3368061D1 (en) 1982-05-11 1987-01-15 Beecham Group Plc Azabicycloalkane derivatives, their preparation and medicaments containing them
EP0101641A3 (en) 1982-07-22 1984-03-28 Beecham Group Plc Sulfonylamino-aza-bicyclo-alkyl derivatives
JPH0731405B2 (ja) 1986-05-02 1995-04-10 キヤノン株式会社 電子写真感光体
JP2699511B2 (ja) 1988-01-29 1998-01-19 武田薬品工業株式会社 置換アミン類
US4897391A (en) * 1988-06-17 1990-01-30 Schering Corporation Tricyclic anti-allergy, antiinflammatory and anti-hyperproliferative compounds
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5140023A (en) 1990-04-27 1992-08-18 G. D. Searle & Co. Azatetracycle compounds
HU213136B (en) 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
JPH04270273A (ja) 1991-02-25 1992-09-25 Kyorin Pharmaceut Co Ltd チアゾリジン−２，４−ジオン誘導体とその塩及びその製造法
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
AU1532492A (en) 1991-04-18 1992-11-17 Dr. Lo Zambeletti S.P.A. Use of heterocyclic compounds for the treatment of inflammatory pain
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
DE69219354T2 (de) 1991-05-10 1997-10-23 Takeda Chemical Industries Ltd Pyridinderivate, deren Herstellung und Anwendung
GB9122859D0 (en) 1991-10-28 1991-12-11 Smithkline Beecham Plc Novel compounds
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH06295078A (ja) 1992-04-24 1994-10-21 Canon Inc 電子写真感光体、該電子写真感光体を備えた電子写真装置並びにファクシミリ
US5840903A (en) 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
US5354757A (en) 1992-12-15 1994-10-11 G. D. Searle & Co. Azanoradamantanes
EP0702671A4 (en) 1993-06-09 1996-06-19 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
DE4333761A1 (de) 1993-10-04 1995-04-06 Luitpold Pharma Gmbh Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel
EP0686625B1 (en) 1993-12-27 1999-05-26 Eisai Co., Ltd. Anthranilic acid derivative
US5530018A (en) 1994-02-04 1996-06-25 G. D. Searle & Co. Meso-azanoradamantanes
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
US5500442A (en) 1994-06-10 1996-03-19 American Home Products Corporation Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants
US5644144A (en) * 1994-09-23 1997-07-01 Advanced Micro Devices, Inc. Device and method for programming a logic level within an integrated circuit using multiple mask layers
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2225255A1 (en) 1995-06-29 1997-01-16 Merck & Co., Inc. Combinations of inhibitors of farnesyl-protein transferase
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
JP3285746B2 (ja) * 1995-11-24 2002-05-27 株式会社資生堂 フェニレンジアミン誘導体及びラジカルスカベンジャー、脳梗塞抑制剤、脳浮腫抑制剤
US5756518A (en) 1996-04-02 1998-05-26 Kowa Co., Ltd. Phenylene derivatives
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
SG124234A1 (en) 1996-07-25 2006-08-30 Biogen Idec Inc Cell adhesion inhibitors
WO1998007421A1 (en) 1996-08-16 1998-02-26 Ishihara Sangyo Kaisha, Ltd. Medicinal composition
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6262068B1 (en) * 1997-02-21 2001-07-17 Bristol-Myers Squibb Company Lactam derivatives as antiarrhythmic agents
DE59802394D1 (de) 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
EP1023291B1 (en) * 1997-10-07 2004-05-26 Ortho-McNeil Pharmaceutical, Inc. Dipyridoimidazolderivatives useful in treating central nervous system disorders
CA2307030A1 (en) 1997-10-24 1999-05-06 Mervyn Thompson Substituted isoquinoline derivatives and their use as anticonvulsants
JP3337992B2 (ja) * 1997-11-04 2002-10-28 ファイザー製薬株式会社 ５−置換ピコリン酸化合物及びその製造方法
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11171774A (ja) 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
EP1051403A1 (en) 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
SE9901875D0 (sv) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
GB9915995D0 (en) 1999-07-09 1999-09-08 Ahmed S Non-steroidal sulphamate compounds for use as oestrone sulphatase inhibitors
NZ516610A (en) 1999-08-04 2004-05-28 Icagen Inc Benzanilides as potassium channel openers
NZ527771A (en) 1999-08-04 2005-04-29 Icagen Inc Methods for treating or preventing anxiety
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
JP2001172258A (ja) 1999-12-17 2001-06-26 Sumitomo Pharmaceut Co Ltd 神経網膜変性疾患の治療薬
WO2001051456A2 (en) 2000-01-13 2001-07-19 Tularik Inc. Antibacterial agents
GB0005366D0 (en) * 2000-03-06 2000-04-26 Xenova Ltd Pharmaceutical compounds
WO2001072712A1 (en) 2000-03-24 2001-10-04 Cor Therapeutics, Inc. ISOQUINOLONE INHIBITORS OF FACTOR Xa
US6545011B2 (en) 2000-07-13 2003-04-08 Guilford Pharmaceuticals Inc. Substituted 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones, derivatives thereof and their uses
US6603013B2 (en) * 2000-07-17 2003-08-05 Merck & Co., Inc. Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids
US20040122223A1 (en) 2001-02-07 2004-06-24 Davis Jeremy Martin Non-natural nucleotides and dinucleotides
JP2002338837A (ja) 2001-05-16 2002-11-27 Fuji Photo Film Co Ltd 新規化合物、色素、インク組成物、インクジェット用インク、インクジェット記録方法、及び熱転写色素
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
EP1414443B1 (en) 2001-08-01 2006-11-15 Merck & Co., Inc. BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES
ATE420644T1 (de) 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
EP1503988B1 (de) 2002-03-26 2009-07-22 Biofrontera Discovery Gmbh Fredericamycin-derivate
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
JP2005538048A (ja) 2002-05-03 2005-12-15 シエーリング アクチエンゲゼルシャフト チアゾリジノン類、それらの生成及び医薬剤としての使用
AU2003281623B8 (en) 2002-07-22 2009-06-11 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivative
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2004203813A (ja) 2002-12-26 2004-07-22 Tokuyama Corp クロメン化合物
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
CA2851462A1 (en) 2003-01-08 2004-07-29 University Of Washington Antibacterial agents
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US20040192728A1 (en) 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
KR20060006047A (ko) 2003-04-28 2006-01-18 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ 인테그레이즈 저해제
MXPA05012086A (es) * 2003-05-12 2006-02-22 Pfizer Prod Inc Inhibidores de benzamida del receptor p2x7.
CN1566099A (zh) 2003-06-13 2005-01-19 中国科学院上海药物研究所 异喹啉－1,3,4－三酮类化合物、制备方法及其用途
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
US7390820B2 (en) * 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
BRPI0415179A (pt) * 2003-10-07 2006-11-28 Renovis Inc derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
TW200530235A (en) * 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
JP2005232175A (ja) 2004-01-21 2005-09-02 Asahi Kasei Pharma Kk ５−置換イソキノリン医薬
EP1737414A2 (en) * 2004-01-23 2007-01-03 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain
US7576099B2 (en) * 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2007109172A2 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0709596A2 (pt) * 2006-03-16 2011-07-19 Renovis Inc compostos bicicloeteroarila como moduladores de p2x7 e seus usos
TWI464148B (zh) * 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
CA2645652A1 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492378B1 (en) * 1998-08-11 2002-12-10 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsivants

Also Published As

Publication number Publication date
HK1136967A1 (zh) 2010-07-16
ES2576643T3 (es) 2016-07-08
CN101686680A (zh) 2010-03-31
EP2124562B1 (en) 2016-04-20
EP2124562A4 (en) 2010-03-10
JP2010520875A (ja) 2010-06-17
DK2124562T3 (en) 2016-08-01
US20080287415A1 (en) 2008-11-20
EP2124562A1 (en) 2009-12-02
WO2008112205A1 (en) 2008-09-18
CA2680275C (en) 2016-08-23
CA2680275A1 (en) 2008-09-18
US8093265B2 (en) 2012-01-10

Similar Documents

Publication Publication Date Title
CN101686680B (zh) 作为p2x7调节剂的双环杂芳基化合物及其用途
CN101442909B (zh) 作为p2x7调节剂的双环杂芳基化合物及其应用
DK1937643T3 (en) Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf
EP2001474B1 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109182A2 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A2 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
EP1865774A1 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
JP2021518388A (ja) オキサジアゾール一過性受容器電位チャネル阻害剤
WO2007109201A2 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007028022A2 (en) Novel compounds as p2x7 modulators and uses thereof
CN101443315B (zh) 作为p2x7调节剂的双环杂芳基化合物及其应用
HK1133787B (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
HK1136967B (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
EP1996585A2 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: EVOTEC US CO., LTD.

Free format text: FORMER OWNER: RENOVIS INC.

Effective date: 20140120

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140120

Address after: American California

Applicant after: Renovis Inc.

Address before: American California

Applicant before: Renovis Inc.

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171129

Address after: American California

Patentee after: Second Genome Corporation

Address before: American California

Patentee before: Renovis Inc.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200914

Address after: American New Jersey

Patentee after: Ivotec America Inc.

Address before: California, USA

Patentee before: SECOND GENOME, INC.